Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

In this Spotlight On Cardio-Oncology, learn about managing cardiovascular-related toxicities in hematological malignancies including CLL, lymphoma, amyloidosis, AML & MDS

Alongside the development of an ever-increasing number of cancer therapies available for patients, cancer survivorship has steadily increased over the past three decades, and the impact on patients has been significant.1 However, with new therapies, comes new challenges, and the management of cancer therapy-related cardiovascular toxicity (CTR-CVT) has become an important consideration for healthcare professionals.2

Chronic Lymphocytic Leukemia (CLL)

Managing cumulative cardiovascular toxicity associated with BTK inhibitors

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA

Continuous BTK inhibitors in CLL treatment: benefits and drawbacks

Kerry Rogers, MD, The Ohio State University, Columbus, OH

Real-world incidence of ibrutinib-related cardiotoxicity in CLL

Lee Greenberger, PhD
Leukemia & Lymphoma Society, New York, NY


Cardiovascular outcomes of patients with FL & DLBCL treated with doxorubicin-based chemotherapy

Vincent Camus, MD, University of Rouen, Rouen, France

MAGNOLIA: zanubrutinib in patients with R/R marginal zone lymphoma

Kim Linton, MBChB, MRCP, PhD, FRCP, The Christie NHS Foundation Trust, Manchester, UK

Investigating the cardiovascular toxicities associated with bispecific
T-cell engagers

Daniel Addison, MD
The Ohio State University Wexner Medical Center, Columbus, OH


CHIP in patients with AL amyloidosis: clinical implications

Paolo Lopedote, MD, St Elizabeth’s Medical Center, Boston, MA

The importance of the MDT to provide adequate treatment and care to patients with amyloidosis

Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy

Acute Myeloid Leukemia (AML) & Myelodysplastic Syndromes (MDS)

Cardiotoxicity of CPX-351 vs 7+3 chemotherapy in AML

Jorge Cortes, MD, Augusta University, Augusta, GA

Clonal hematopoiesis in AML & insights into a novel CHIP risk stratification score

Benjamin Ebert, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

MCL-1 inhibition with AZD5991 in R/R hematologic malignancies

Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York City, NY


  1. Vaz-Luis I, et al. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol 2022;33:1119–33.
  2. Lyon A, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022;23:e333–e465.


AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTR-CVT, cancer-therapy cardiovascular-related toxicity; MDS, myelodysplastic syndromes.


This educational activity has received independent medical education support from Johnson & Johnson. This supporter has no influence over the production of the content.